Results 11 to 20 of about 580 (130)

Catalytic Static Mixer-Enabled Hydrogenation of a Key Fenebrutinib Intermediate: Real-Time Analysis for a Stable and Scalable Process [PDF]

Organic Process Research & Development, 2021
Catalytic static mixer (CSM) technology is presented as an industrially-viable solution for an aromatic nitro group reduction in the synthesis of fenebrutinib. Factors effecting catalyst inhibition could be rapidly understood and mitigated by the use of real-time analytics (FT-IR, UHPLC).
René Lebl, Stephan Bachmann, Paolo Tosatti, Joerg Sedelmeier, Kurt Püntener, Jason D. Williams, C. Oliver Kappe   +6 more
openaire   +3 more sources

Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Blood Advances, 2019
: Activation of the platelet Fc-receptor CD32a (FcγRIIA) is an early and crucial step in the pathogenesis of heparin-induced thrombocytopenia type II (HIT) that has not been therapeutically targeted.
Luise Goldmann, Rundan Duan, Thorsten Kragh, Georg Wittmann, Christian Weber, Reinhard Lorenz, Philipp von Hundelshausen, Michael Spannagl, Wolfgang Siess   +8 more
doaj   +2 more sources

Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib, and fenebrutinib

Journal of Leukocyte Biology
Abstract Multiple sclerosis (MS) is a neurodegenerative, autoimmune disease that is still incurable. Nowadays, a variety of new drugs are being developed to prevent excessive inflammation and halt neurodegeneration. Among these are the inhibitors of Bruton's tyrosine kinase (BTK).
De Bondt, Mirre, Renders, Janne, de Prado, Paloma Petit, Berghmans, Nele, Portner, Nomie, Vanbrabant, Lotte, de Oliveira, Vivian Louise Soares, Duran, Gayel, Baeten, Paulien, Broux, Bieke, Gouwy, Mieke, Matthys, Patrick, Hellings, Niels, Struyf, Sofie   +13 more
openaire   +5 more sources

FRI0129 THE BTK INHIBITOR, FENEBRUTINIB, EFFECTIVELY MODULATES B AND MYELOID CELL BIOLOGY IN RHEUMATOID ARTHRITIS PATIENTS [PDF]

Annals of the Rheumatic Diseases, 2019
Background: Bruton’s tyrosine kinase (BTK) plays an essential role in B cell development. BTK acts downstream of the B cell receptor in B cells, and Fc receptor signaling in myeloid cells, pathways thought to be involved in the pathogenesis of RA.
Alyssa Morimoto, Julie Rae, Leslie Chinn, Nandhini Ramamoorthi, Olivia Hwang, Alexandra Ward, D. James Haddon, Caroline Looney, Rupal Desai, Balazs Toth, Katie Tuckwell, Michael J. Townsend   +11 more
openaire   +2 more sources

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Systemic Lupus Erythematosus

, 2021
BACKGROUND: Fenebrutinib (GDC-0853, FEN) is a non-covalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of FEN were assessed in this randomized, placebo-controlled, multi-center phase
Isenberg, D, Furie, R, Jones, NS, Guibord, P, Galanter, J, Lee, C, McGregor, A, Toth, B, Rae, J, Hwang, O, Desai, R, Lokku, A, Ramamoorthi, N, Hackney, JA, Miranda, P, de Souza, VA, Jaller-Raad, JJ, Maura Fernandes, A, Garcia Salinas, R, Chinn, LW, Townsend, MJ, Morimoto, AM, Tuckwell, K   +22 more
openaire   +2 more sources

Research progress in targeted therapies of chronic lymphocytic leukemia [PDF]

Shanghai Jiaotong Daxue xuebao. Yixue ban
Chronic lymphocytic leukemia (CLL) is one of small B-cell lymphomas and leukemias, characterized as a clonal disease of mature B cells. The disease is remarkably heterogeneous, with the majority of patients having an indolent course, yet they are ...
DING Yanling, LI Jie, YUAN Jun, LI Yan
doaj   +2 more sources

Fenebrutinib [PDF]

, 2020
openaire   +2 more sources

Bruton’s Tyrosine Kinase Inhibitors and Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Review of Complementary Paradigms for a Divergent Disease

Sclerosis
Multiple sclerosis (MS) is a heterogeneous autoimmune disease driven by peripheral immune dysregulation and compartmentalized central nervous system (CNS) inflammation. Despite more than 20 approved disease-modifying therapies, disability accrual remains
Wilhelmina Hauwanga, Mariyam Fathima Salim, Maha Awan, Lynda Amaka Ezike, Ida Ann Veronica Fredrick Luther, Mustafa Suliman, Jeshua Nathaniel Devan, Billy McBenedict   +7 more
doaj   +2 more sources

Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib and fenebrutinib affect neutrophil functions in vitro: implications for treatment of autoimmune disease

Purpose: Multiple sclerosis (MS) is a neurodegenerative, autoimmune disease that is still incurable. Nowadays, a variety of new drugs are being developed to prevent excessive inflammation and halt neurodegeneration. Among these are the inhibitors of Bruton's tyrosine kinase (BTK).
DE BONDT, Mirre, Renders, Janne, de Prado, Paloma Petit, Berghmans, Nele, Portner, Noemie, VANBRABANT, Lotte, DURAN, Gayel, BAETEN, Paulien, BROUX, Bieke, Gouwy , Mieke, Matthys, Patrick, HELLINGS, Niels, Struyf, Sofie   +12 more
core   +3 more sources

The Neurovascular Niche: A Gathering Venue for Neuroinflammation and Remyelination in Multiple Sclerosis. [PDF]

Acta Physiol (Oxf)
ABSTRACT In the central nervous system (CNS), the tissue microenvironment is continuously monitored and regulated to secure the unobstructed function of neurons and of their networks. This is a key function of the neurovascular niche (NVN), which is the interface between the cells of the nervous tissue and the cells and the content of blood vessels. It
Kazanis I, Silva ME, de la Fuente AG, de Castro F, Rivera FJ.   +4 more
europepmc   +2 more sources